Cost-Effectiveness of Empagliflozin in the UK in an EMPA-REG OUTCOME Subgroup with Type 2 Diabetes and Heart Failure

Abstract

This analysis suggests that adding empagliflozin to SoC in HF patients with T2D constitutes a cost-effective use of UK healthcare resources and may provide long-term health benefits to patients.